GVAG
MRNA icon

Great Valley Advisor Group’s Moderna MRNA Stock Holding History

Great Valley Advisor Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,334
Closed -$208K – 926
2025
Q1 		$208K Buy
7,334
+141
+2% +$5K ﹤0.01% 825
2024
Q4 		$299K Sell
7,193
-55
-0.8% -$2.63K 0.01% 695
2024
Q3 		$485K Sell
7,248
-95
-1% -$8.72K 0.01% 568
2024
Q2 		$872K Sell
7,343
-631
-8% -$79.9K 0.02% 412
2024
Q1 		$849K Buy
7,974
+183
+2% +$18.4K 0.03% 399
2023
Q4 		$775K Sell
7,791
-503
-6% -$42.3K 0.03% 380
2023
Q3 		$857K Sell
8,294
-407
-5% -$45.4K 0.04% 342
2023
Q2 		$1.06M Sell
8,701
-229
-3% -$30.5K 0.04% 306
2023
Q1 		$1.37M Buy
8,930
+3,698
+71% +$610K 0.06% 262
2022
Q4 		$940K Buy
5,232
+2,786
+114% +$456K 0.05% 333
2022
Q3 		$289K Sell
2,446
-1,714
-41% -$260K 0.02% 542
2022
Q2 		$595K Buy
4,160
+1,348
+48% +$193K 0.03% 395
2022
Q1 		$490K Buy
2,812
+99
+4% +$16.7K 0.03% 391
2021
Q4 		$695K Sell
2,713
-7,998
-75% -$2.34M 0.04% 323
2021
Q3 		$4.12M Buy
10,711
+4,734
+79% +$1.75M 0.28% 90
2021
Q2 		$1.4M Sell
5,977
-403
-6% -$72K 0.1% 205
2021
Q1 		$835K Sell
6,380
-2,049
-24% -$297K 0.08% 220
2020
Q4 		$881K Sell
8,429
-781
-8% -$79K 0.09% 200
2020
Q3 		$651K Sell
9,210
-2,522
-21% -$176K 0.08% 204
2020
Q2 		$753K Sell
11,732
-645
-5% -$35.3K 0.12% 179
2020
Q1 		$370K Buy
+12,377
New +$285K 0.1% 216

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Great Valley Advisor Group's MRNA Position: Q2 2025 in Review

Great Valley Advisor Group sold out of Moderna (MRNA) in Q2 2025, closing a stake of 7,334 shares — an estimated $208K sold.

Great Valley Advisor Group first reported a position in MRNA in Q1 2020 and held it in 21 quarters. The position peaked at $4.12M in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Great Valley Advisor Group reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Great Valley Advisor Group sold 7,334 Moderna shares in Q2 2025, an estimated $208K.
  • Great Valley Advisor Group first reported a position in Moderna in Q1 2020 and held it in 21 quarters.
  • Great Valley Advisor Group's Moderna position peaked at $4.12M in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Great Valley Advisor Group's 13F filing for Q2 2025, filed 14 Aug 2025.